# Acceptability and Feasibility of TruGraf® Testing as Part of the Standard of Care

> **NCT04267016** · — · TERMINATED · sponsor: **Transplant Genomics, Inc.** · enrollment: 26 (actual)

## Conditions studied

- Kidney Transplant Rejection

## Interventions

- **DIAGNOSTIC_TEST:** TruGraf Testing - Peripheral blood gene expression profiling

## Key facts

- **NCT ID:** NCT04267016
- **Lead sponsor:** Transplant Genomics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2020-08-19
- **Primary completion:** 2021-05-11
- **Final completion:** 2021-05-11
- **Target enrollment:** 26 (ACTUAL)
- **Why stopped:** Sponsor decision to cancel study
- **Last updated:** 2021-09-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04267016

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04267016, "Acceptability and Feasibility of TruGraf® Testing as Part of the Standard of Care". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04267016. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*